Advances and future challenges in adenoviral vector pharmacology and targeting

Reeti Khare, Christopher Y. Chen, Eric A Weaver, Michael A. Barry

Research output: Contribution to journalReview article

99 Citations (Scopus)

Abstract

Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multifaceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In the rational design of vectors, the notion of overcoming a sequence of viral "sinks" must be combined with re-targeting to target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2. However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substantial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic effect.

Original languageEnglish (US)
Pages (from-to)241-258
Number of pages18
JournalCurrent Gene Therapy
Volume11
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Adenoviridae
Pharmacology
Kupffer Cells
Health Services Needs and Demand
Poisons
Capsid
Therapeutic Uses
Immunity
Viruses
Serogroup
Research
Therapeutics

Keywords

  • Ad serotypes
  • Liver
  • Sequestration
  • Serotypes
  • Targeting

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Advances and future challenges in adenoviral vector pharmacology and targeting. / Khare, Reeti; Chen, Christopher Y.; Weaver, Eric A; Barry, Michael A.

In: Current Gene Therapy, Vol. 11, No. 4, 01.08.2011, p. 241-258.

Research output: Contribution to journalReview article

Khare, Reeti ; Chen, Christopher Y. ; Weaver, Eric A ; Barry, Michael A. / Advances and future challenges in adenoviral vector pharmacology and targeting. In: Current Gene Therapy. 2011 ; Vol. 11, No. 4. pp. 241-258.
@article{8787fae964d4442dbf77c3870af905ba,
title = "Advances and future challenges in adenoviral vector pharmacology and targeting",
abstract = "Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multifaceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In the rational design of vectors, the notion of overcoming a sequence of viral {"}sinks{"} must be combined with re-targeting to target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2. However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substantial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic effect.",
keywords = "Ad serotypes, Liver, Sequestration, Serotypes, Targeting",
author = "Reeti Khare and Chen, {Christopher Y.} and Weaver, {Eric A} and Barry, {Michael A.}",
year = "2011",
month = "8",
day = "1",
doi = "10.2174/156652311796150363",
language = "English (US)",
volume = "11",
pages = "241--258",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Advances and future challenges in adenoviral vector pharmacology and targeting

AU - Khare, Reeti

AU - Chen, Christopher Y.

AU - Weaver, Eric A

AU - Barry, Michael A.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multifaceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In the rational design of vectors, the notion of overcoming a sequence of viral "sinks" must be combined with re-targeting to target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2. However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substantial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic effect.

AB - Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multifaceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In the rational design of vectors, the notion of overcoming a sequence of viral "sinks" must be combined with re-targeting to target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2. However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substantial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic effect.

KW - Ad serotypes

KW - Liver

KW - Sequestration

KW - Serotypes

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=79960016902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960016902&partnerID=8YFLogxK

U2 - 10.2174/156652311796150363

DO - 10.2174/156652311796150363

M3 - Review article

VL - 11

SP - 241

EP - 258

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 4

ER -